PE20051095A1 - DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA - Google Patents
DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASAInfo
- Publication number
- PE20051095A1 PE20051095A1 PE2005000121A PE2005000121A PE20051095A1 PE 20051095 A1 PE20051095 A1 PE 20051095A1 PE 2005000121 A PE2005000121 A PE 2005000121A PE 2005000121 A PE2005000121 A PE 2005000121A PE 20051095 A1 PE20051095 A1 PE 20051095A1
- Authority
- PE
- Peru
- Prior art keywords
- ilbenzoil
- carboxamide
- amino
- pirazole
- alkyl
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 1-METHYL-1-PHENYLETHYL Chemical class 0.000 abstract 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 abstract 2
- 102000003989 Aurora kinases Human genes 0.000 abstract 1
- 108090000433 Aurora kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 1H-TIENO[2,3-c]PIRAZOL DE FORMULA (I); EN DONDE R ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO; R1 Y R2 SON, INDEPENDIENTEMENTE ENTRE SI, H, ALQUILO(C1-C3) LINEAL O RAMIFICADO, -CONH2, CH2NR'R" O JUNTOS CON EL ATOMO DE C AL QUE ESTAN UNIDOS FORMAN CICLOALQUILO(C3-C6); R' Y R" SON INDEPENDIENTEMENTE H, ALQUILO(C1-C3), O JUNTOS CON EL N AL QUE ESTAN UNIDOS PUEDEN FORMAR ANILLO HETEROCICLICO COMO PIRROLIDINIL-1-IL, AZETIDINIL-1-ILO, ENTRE OTROS; R3 ES H, HALOGENO, -OH, CIANO, ALQUILO(C1-C3) LINEAL O RAMIFICADO O ALCOXI(C1-C6). SON COMPUESTOS PREFERIDOS: N(1-METIL-1-FENILETIL)-3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-1H-TIENO[2,3-C]PIRAZOL-5-CARBOXAMIDA, 3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-N-(1-FENILCICLOPROPIL)-1H-TIENO[2,3-C] PIRAZOL-5-CARBOXAMIDA, N-[(1R)-1-(FLUOROFENIL)ETIL]-3-[(4-MORFOLIN-4-ILBENZOIL)AMINO]-1H-TIENO[2,3-C]PIRAZOL-5-CARBOXAMIDA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCESO DE ELABORACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA, PARTICULARMENTE DE AURORA QUINASA, POR LO QUE SON UTILES EN EL TRATAMIENTO DE CANCER Y TRANSTORNOS DE PROLIFERACION CELULAR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54145204P | 2004-02-03 | 2004-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051095A1 true PE20051095A1 (es) | 2005-12-31 |
Family
ID=34837492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000121A PE20051095A1 (es) | 2004-02-03 | 2005-02-02 | DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8138217B2 (es) |
| EP (1) | EP1711177B1 (es) |
| JP (1) | JP4908233B2 (es) |
| KR (1) | KR20060124734A (es) |
| CN (1) | CN1946395B (es) |
| AP (1) | AP2006003701A0 (es) |
| AR (1) | AR047531A1 (es) |
| AT (1) | ATE396724T1 (es) |
| AU (1) | AU2005210114B2 (es) |
| BR (1) | BRPI0507375A (es) |
| CA (1) | CA2555262C (es) |
| CR (1) | CR8546A (es) |
| CY (1) | CY1108246T1 (es) |
| DE (1) | DE602005007181D1 (es) |
| DK (1) | DK1711177T3 (es) |
| DO (1) | DOP2005000014A (es) |
| EA (1) | EA011032B1 (es) |
| EC (1) | ECSP066767A (es) |
| ES (1) | ES2307144T3 (es) |
| GE (1) | GEP20094633B (es) |
| GT (1) | GT200500020A (es) |
| IL (1) | IL177141A0 (es) |
| MA (1) | MA28429B1 (es) |
| MX (1) | MXPA06008787A (es) |
| NO (1) | NO20063768L (es) |
| NZ (1) | NZ548896A (es) |
| PA (1) | PA8622801A1 (es) |
| PE (1) | PE20051095A1 (es) |
| PL (1) | PL1711177T3 (es) |
| PT (1) | PT1711177E (es) |
| SI (1) | SI1711177T1 (es) |
| TN (1) | TNSN06244A1 (es) |
| TW (1) | TW200526204A (es) |
| UA (1) | UA86223C2 (es) |
| UY (1) | UY28738A1 (es) |
| WO (1) | WO2005074922A1 (es) |
| ZA (1) | ZA200606179B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2493680C (en) * | 2002-07-25 | 2010-09-07 | Pharmacia Italia S.P.A. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| JP5303271B2 (ja) * | 2005-07-19 | 2013-10-02 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物 |
| AU2006298563A1 (en) * | 2005-10-06 | 2007-04-12 | Merck & Co., Inc. | Use of fused pyrrole carboxylic acids for the treatment of neurodegenerative and psychiatric diseases as D-amino acid oxidase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| ATE524177T1 (de) | 2006-03-30 | 2011-09-15 | Nerviano Medical Sciences Srl | Verwendung eines kinasehemmers zur behandlung von bestimmten resistenten tumoren |
| EP2051981B1 (en) * | 2006-05-31 | 2010-08-25 | Nerviano Medical Sciences S.R.L. | 1h-furo[3,2-c] pyrazole compounds useful as kinase inhibitors |
| FR2904626B1 (fr) | 2006-08-03 | 2008-09-19 | Sanofi Aventis | Derives de pyrazolo[4,3]thiazole, leur preparation et leur application en therapeutique |
| SG175609A1 (en) | 2006-10-09 | 2011-11-28 | Takeda Pharmaceutical | Kinase inhibitors |
| KR100923540B1 (ko) | 2007-11-23 | 2009-10-27 | 한국과학기술연구원 | 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법 |
| AR071780A1 (es) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
| US8569512B2 (en) | 2009-03-23 | 2013-10-29 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| US9255072B2 (en) | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
| ES2929759T3 (es) * | 2012-04-05 | 2022-12-01 | Nerviano Medical Sciences Srl | Nuevos agentes alquilantes |
| US11466024B2 (en) | 2017-08-01 | 2022-10-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicylic compound acting as an inhibitor |
| AU2018375456B2 (en) * | 2017-11-30 | 2021-11-18 | Hanmi Pharm. Co., Ltd. | Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase |
| CN113072562B (zh) * | 2021-04-06 | 2022-01-14 | 山东大学 | 一种GSK-3β抑制剂及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3763409D1 (de) | 1986-02-19 | 1990-08-02 | Duphar Int Res | Thio-verbindungen und ihre wirkung als fungizide. |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| HK1046866A1 (zh) | 1999-08-12 | 2003-01-30 | 法玛西雅意大利公司 | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 |
| BR0113176A (pt) * | 2000-08-10 | 2003-06-17 | Pharmacia Italia Spa | Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos |
| AU2002215053A1 (en) | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| CA2434066A1 (en) | 2001-01-26 | 2002-09-12 | Pharmacia Italia S.P.A. | Chromane derivatives, process for their preparation and their use as antitumor agents |
| BR0212841A (pt) | 2001-09-26 | 2004-08-03 | Pharmacia Italia Spa | Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém |
| EP1506176B1 (en) * | 2002-05-17 | 2013-04-24 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2004007504A1 (en) * | 2002-07-17 | 2004-01-22 | Pharmacia Italia S.P.A. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
| CA2493680C (en) * | 2002-07-25 | 2010-09-07 | Pharmacia Italia S.P.A. | Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| US20050026984A1 (en) * | 2003-07-29 | 2005-02-03 | Aventis Pharma S.A. | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products |
-
2005
- 2005-01-28 TW TW094102761A patent/TW200526204A/zh unknown
- 2005-02-02 CA CA2555262A patent/CA2555262C/en not_active Expired - Fee Related
- 2005-02-02 WO PCT/EP2005/001021 patent/WO2005074922A1/en not_active Ceased
- 2005-02-02 UA UAA200609515A patent/UA86223C2/uk unknown
- 2005-02-02 KR KR1020067017754A patent/KR20060124734A/ko not_active Ceased
- 2005-02-02 PT PT05701307T patent/PT1711177E/pt unknown
- 2005-02-02 ES ES05701307T patent/ES2307144T3/es not_active Expired - Lifetime
- 2005-02-02 AP AP2006003701A patent/AP2006003701A0/xx unknown
- 2005-02-02 DE DE602005007181T patent/DE602005007181D1/de not_active Expired - Lifetime
- 2005-02-02 EP EP05701307A patent/EP1711177B1/en not_active Expired - Lifetime
- 2005-02-02 MX MXPA06008787A patent/MXPA06008787A/es active IP Right Grant
- 2005-02-02 PL PL05701307T patent/PL1711177T3/pl unknown
- 2005-02-02 AR ARP050100399A patent/AR047531A1/es not_active Application Discontinuation
- 2005-02-02 AU AU2005210114A patent/AU2005210114B2/en not_active Ceased
- 2005-02-02 BR BRPI0507375-8A patent/BRPI0507375A/pt not_active IP Right Cessation
- 2005-02-02 DK DK05701307T patent/DK1711177T3/da active
- 2005-02-02 CN CN200580005922.0A patent/CN1946395B/zh not_active Expired - Fee Related
- 2005-02-02 JP JP2006551790A patent/JP4908233B2/ja not_active Expired - Fee Related
- 2005-02-02 SI SI200530297T patent/SI1711177T1/sl unknown
- 2005-02-02 EA EA200601418A patent/EA011032B1/ru not_active IP Right Cessation
- 2005-02-02 GE GEAP20059600A patent/GEP20094633B/en unknown
- 2005-02-02 AT AT05701307T patent/ATE396724T1/de active
- 2005-02-02 PE PE2005000121A patent/PE20051095A1/es not_active Application Discontinuation
- 2005-02-02 NZ NZ548896A patent/NZ548896A/en unknown
- 2005-02-02 DO DO2005000014A patent/DOP2005000014A/es unknown
- 2005-02-03 PA PA20058622801A patent/PA8622801A1/es unknown
- 2005-02-03 UY UY28738A patent/UY28738A1/es not_active Application Discontinuation
- 2005-02-03 GT GT200500020A patent/GT200500020A/es unknown
- 2005-02-03 US US11/050,360 patent/US8138217B2/en not_active Expired - Fee Related
-
2006
- 2006-07-26 ZA ZA200606179A patent/ZA200606179B/xx unknown
- 2006-07-27 IL IL177141A patent/IL177141A0/en unknown
- 2006-08-03 TN TNP2006000244A patent/TNSN06244A1/fr unknown
- 2006-08-03 CR CR8546A patent/CR8546A/es not_active Application Discontinuation
- 2006-08-03 MA MA29227A patent/MA28429B1/fr unknown
- 2006-08-10 EC EC2006006767A patent/ECSP066767A/es unknown
- 2006-08-23 NO NO20063768A patent/NO20063768L/no not_active Application Discontinuation
-
2008
- 2008-08-07 CY CY20081100834T patent/CY1108246T1/el unknown
-
2012
- 2012-02-24 US US13/404,697 patent/US8481584B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051095A1 (es) | DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20050081A1 (es) | Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas | |
| ATE490253T1 (de) | Synthese von 5-substituierten 7-azaindolen und 7- azaindolinen | |
| PE20080059A1 (es) | Quinazolinas para la inhibicion de pdk1 | |
| PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
| PE20060664A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| BRPI0413233A (pt) | novos compostos | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| TNSN07196A1 (en) | Potentiators of glutamate receptors | |
| PE20120034A1 (es) | Compuestos derivados de n-fenilpirimidin-2-amina | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| MX2007003603A (es) | Metodos para preparar compuestos de indazol. | |
| DE602004011924D1 (de) | Chinazoline derivate und ihre anwendung in der krebsbehandlung | |
| PE20081496A1 (es) | Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1 | |
| PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| PE20081492A1 (es) | Derivados de sulfonamida heterociclicos como antagonista de edg-1 | |
| ATE368666T1 (de) | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |